September 15, 2021: Francis Medical today announced the completion of the company’s $55.0 million Series B equity financing. The company plans to use the Series B proceeds to fund the development of its proprietary prostate cancer treatment through FDA 510(k) approval, which includes a pivotal clinical study (VAPOR 2) for the management of prostate cancer, scheduled to begin enrollment in August 2022.
June 8, 2021: Francis Medical announces positive data from its Vapor 1 IDE Study for water vapor ablation of prostate cancer. These promising results support the intent of this therapy to manage clinically significant disease while decreasing morbidities associated with currently used prostate cancer treatments.
CAUTION: Investigational device. Limited by United States law to investigational use.
7351 Kirkwood Lane N., Suite 130, Maple Grove, MN 55369
Phone: 763-951-0370
Email: info@francismedical.com
Developing novel, disruptive therapeutic solutions to treat prostate, kidney and bladder cancer.
© Copyright Francis Medical, Inc. 2025 | ALL RIGHTS RESERVED | 4206-001_04